Answers are grounded in this paper and cite their sources.
BACKGROUND: Despite the fact that immunotherapy is reshaping the therapeutic landscape of bladder cancer, immune evasion remains a major obstacle to durable clinical benefit. Therefore, elucidating the mechanisms underlying immune resistance is essential for developing novel therapeutic strategies. METHODS: In this study, we performed a genome-wide CRISPR-Cas9 screen in bladder cancer cells co-cultured with CD8(+) T cells and identified the SLP adaptor and CSK-interacting membrane protein (SCIMP) as a key gene that enhances CD8(+) T cell antitumor immunity. RESULTS: SCIMP serves as a favorable prognostic biomarker in patients with bladder cancer treated with immunotherapy. Mechanistically, SCIMP restricts JAK1 phosphorylation in an adaptor-independent manner, suppressing the IFN-γ/JAK1/STAT5A/PD-L1 signaling axis. Meanwhile, YTHDF2 destabilizes the m6A-tagged SCIMP transcripts to reduce their expression. Remarkably, SCIMP synergizes with PD-1 blockade in suppressing tumor growth. CONCLUSIONS: Collectively, these findings reveal a previously unexplored non-canonical role of SCIMP in preventing immune evasion and provide a potential therapeutic target for bladder cancer.
No takes yet. Share an insight, caveat, or question.
游永强 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: